ATE187724T1 - Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
ATE187724T1
ATE187724T1 AT93114934T AT93114934T ATE187724T1 AT E187724 T1 ATE187724 T1 AT E187724T1 AT 93114934 T AT93114934 T AT 93114934T AT 93114934 T AT93114934 T AT 93114934T AT E187724 T1 ATE187724 T1 AT E187724T1
Authority
AT
Austria
Prior art keywords
azachinoxalines
production
formula
image
substituents
Prior art date
Application number
AT93114934T
Other languages
German (de)
English (en)
Inventor
Uta-Maria Billhardt-Troughton
Manfred Dr Roesner
Rudolf Dr Bender
Christoph Dr Meichsner
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of ATE187724T1 publication Critical patent/ATE187724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Radar Systems Or Details Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT93114934T 1992-09-26 1993-09-16 Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung ATE187724T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4232392 1992-09-26

Publications (1)

Publication Number Publication Date
ATE187724T1 true ATE187724T1 (de) 2000-01-15

Family

ID=6468974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93114934T ATE187724T1 (de) 1992-09-26 1993-09-16 Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung

Country Status (20)

Country Link
US (1) US5424311A (index.php)
EP (1) EP0590428B1 (index.php)
JP (1) JPH06211855A (index.php)
KR (1) KR940007035A (index.php)
AT (1) ATE187724T1 (index.php)
AU (1) AU664643B2 (index.php)
CA (1) CA2106882C (index.php)
CZ (1) CZ9302005A3 (index.php)
DE (1) DE59309902D1 (index.php)
DK (1) DK0590428T3 (index.php)
ES (1) ES2141744T3 (index.php)
GR (1) GR3032520T3 (index.php)
HU (1) HUT65302A (index.php)
IL (1) IL107081A (index.php)
MX (1) MX9305894A (index.php)
NZ (1) NZ248762A (index.php)
PH (1) PH30348A (index.php)
PT (1) PT590428E (index.php)
TW (1) TW274550B (index.php)
ZA (1) ZA937081B (index.php)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995018616A2 (en) * 1994-01-03 1995-07-13 Acea Pharm Inc 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/nmda receptor
US5801183A (en) * 1995-01-27 1998-09-01 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Aza and aza (N-oxy) analogs of glycine/NMDA receptor antagonists
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
DE69916414T2 (de) 1998-07-16 2005-05-19 Aaron Tabor Sojazubereitungen und deren verwendung zur gesundheitsförderung
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
AU2003220401A1 (en) 2002-03-18 2003-10-08 Bristol-Myers Squibb Company Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PL1636228T3 (pl) * 2003-05-23 2009-04-30 Aeterna Zentaris Gmbh Nowe pirydopirazyny i ich zastosowanie jako modulatorów kinazy
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) * 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
MX2008012456A (es) * 2006-04-21 2008-10-10 Pfizer Prod Inc Piridin[3,4-b]pirazinonas.
US7601716B2 (en) * 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
GB0614471D0 (en) * 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
CA2666624C (en) * 2006-10-19 2015-12-29 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
CN101573360A (zh) * 2006-10-19 2009-11-04 西格诺药品有限公司 杂芳基化合物、其组合物以及它们作为蛋白激酶抑制剂的用途
US8372114B2 (en) * 2006-11-13 2013-02-12 Electroformed Stents, Inc. Over-the-wire exclusion device and system for delivery
EP3098223A1 (en) * 2007-08-03 2016-11-30 Boehringer Ingelheim International GmbH Crystalline form of a dihydropteridione derivative
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
SI2364314T1 (sl) 2008-12-09 2014-07-31 Gilead Sciences, Inc. Modulatorji Tollu podobnih receptorjev
EA020301B1 (ru) * 2009-01-23 2014-10-30 Такеда Фармасьютикал Компани Лимитед Ингибиторы поли(адф-рибозо)полимеразы (parp)
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
AU2010292102B2 (en) * 2009-09-14 2015-04-09 Gilead Sciences, Inc. Modulators of Toll-like receptors
WO2011053518A1 (en) * 2009-10-26 2011-05-05 Signal Pharmaceuticals, Llc Methods of synthesis and purification of heteroaryl compounds
JP6114554B2 (ja) * 2010-02-03 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
TWI713752B (zh) 2011-10-19 2020-12-21 標誌製藥公司 以ｔｏｒ激酶抑制劑治療癌症
WO2013071217A1 (en) 2011-11-10 2013-05-16 OSI Pharmaceuticals, LLC Dihydropteridinones
EA026390B1 (ru) 2011-12-02 2017-04-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ 7-(6-(2-ГИДРОКСИПРОПАН-2-ИЛ)ПИРИДИН-3-ИЛ)-1-((ТРАНС)-4-МЕТОКСИЦИКЛОГЕКСИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА, ИХ ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TWI615143B (zh) 2012-02-24 2018-02-21 標誌製藥公司 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
KR102221029B1 (ko) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 디하이드로피라지노-피라진을 사용한 암의 치료
KR102240356B1 (ko) 2013-04-17 2021-04-14 시그날 파마소티칼 엘엘씨 Ｔｏｒ 키나제 억제제와 5-치환된 퀴나졸리논 화합물을 포함하는 암 치료용 조합 요법
EP2986609B1 (en) 2013-04-17 2019-06-19 Signal Pharmaceuticals, LLC Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
EP2986319A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
US9630966B2 (en) 2013-04-17 2017-04-25 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
WO2015160868A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
US9718824B2 (en) 2014-04-16 2017-08-01 Signal Pharmaceuticals, Llc Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
PL3166607T3 (pl) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulatory receptorów toll-podobnych do leczenia hiv
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
US9738646B2 (en) 2014-09-16 2017-08-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
SI3461828T1 (sl) 2014-09-16 2021-01-29 Gilead Sciences, Inc. Postopki za pripravo modulatorjev toličnega receptorja
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
KR102272284B1 (ko) * 2020-01-13 2021-07-02 금오공과대학교 산학협력단 정밀 압력제어가 가능한 다단 스프링 압력제어밸브
WO2025085564A1 (en) * 2023-10-16 2025-04-24 Kronos Bio, Inc. Lysine acetyltransferase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4077955A (en) * 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
PH15791A (en) * 1978-10-20 1983-03-25 Lilly Co Eli Pharmaceutical composition containing 3,4-dihydro-3-oxoquinoxalines
IE58312B1 (en) * 1984-05-18 1993-09-08 Union Pharma Scient Appl Heterocyclic derivatives, processes for their preparation and drugs in which they are present, which are useful especially as aldose reductase inhibitors
JPH0276860A (ja) * 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DK160876C (da) * 1987-12-08 1991-10-14 Novo Nordisk As Imidazoquinoxalinforbindelser, fremgangsmaade til deres fremstilling, anvendelse af forbindelserne og farmaceutiske praeparater, hvori forbindelserne indgaar
ES2164639T3 (es) * 1991-04-15 2002-03-01 Aventis Pharma Gmbh Quinoxalinas, procedimiento para su preparacion y su empleo.

Also Published As

Publication number Publication date
KR940007035A (ko) 1994-04-26
GR3032520T3 (en) 2000-05-31
PH30348A (en) 1997-04-02
ZA937081B (en) 1994-04-18
US5424311A (en) 1995-06-13
HU9302696D0 (en) 1993-12-28
CA2106882C (en) 2007-04-17
JPH06211855A (ja) 1994-08-02
TW274550B (index.php) 1996-04-21
IL107081A0 (en) 1993-12-28
DK0590428T3 (da) 2000-05-22
HUT65302A (en) 1994-05-02
ES2141744T3 (es) 2000-04-01
MX9305894A (es) 1994-03-31
PT590428E (pt) 2000-04-28
CA2106882A1 (en) 1994-03-27
AU4755393A (en) 1994-03-31
AU664643B2 (en) 1995-11-23
EP0590428B1 (de) 1999-12-15
CZ9302005A3 (en) 1994-04-13
IL107081A (en) 1999-07-14
NZ248762A (en) 1996-01-26
EP0590428A1 (de) 1994-04-06
DE59309902D1 (de) 2000-01-20

Similar Documents

Publication Publication Date Title
ATE187724T1 (de) Azachinoxaline, verfahren zu ihrer herstellung und ihre verwendung
ATE205837T1 (de) Chinoxaline, verfahren zu ihrer herstellung und ihre verwendung
ATE230732T1 (de) Imidazol-derivate mit biphenylsulfonylharnstoff- oder biphenylsulfonylurethan-seitenkette, verfahren zu ihrer herstellung und ihre verwendung
ATE20738T1 (de) Chinolinderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE3482180D1 (de) Cyclohexenol-derivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE3576955D1 (de) Beta-carbolin-3-oxadiazolylderivate, verfahren zu ihrer herstellung und ihre verwendung.
PT77924B (de) Disubstituierte prolinderivate verfahren zu ihrer herstellung und ihre verwendung
ATE181056T1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
ATE104296T1 (de) Substituierte 1,2,4-triazindione, verfahren zu ihrer herstellung und ihre verwendung.
DE3578178D1 (de) Beta-carbolin-3-carbonsaeurederivate, verfahren zu ihrer herstellung und ihre verwendung.
ATE184003T1 (de) 4-iminochinoline, verfahren zu ihrer herstellung und ihre verwendung
DE3673468D1 (de) N-alkyl-2,6-dimethylmorpholinio-carbonsaeureamid-salze, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
ATE66209T1 (de) Dihydropyridinamide, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln.
ATE14577T1 (de) Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses.
DE59905700D1 (de) N-phenylacetoacetamide und Verfahren zu ihrer Herstellung
ATE85327T1 (de) Substituierte pyridylethanolamine, verfahren zu ihrer herstellung und ihre verwendung als leistungsfoerderer bei tieren.
ATE8046T1 (de) Dibenzofuranderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von pilzen.
ATE8390T1 (de) Vinylazole, verfahren zu ihrer herstellung und ihre verwendung bei der bekaempfung von pilzen.
ATE9337T1 (de) N-substituierte 2-methylnaphthylamide, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung von pilzen.
DE3851979D1 (de) Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE3578866D1 (de) 2,3-diamino-2,3-didesoxyhexose-derivate, verfahren zu ihrer herstellung und ihre verwendung.
DE59001431D1 (de) 1-methoxypyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeurenitroanilide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung.
ATE111903T1 (de) Substituierte 1.2.3.4-oxatriazolium-5-olate, verfahren zu ihrer herstellung und ihre verwendung.
ATE66463T1 (de) 1,4-cyclohexandiamine, verfahren zu ihrer herstellung und ihre verwendung als fungizide.
DE3868948D1 (de) 4,4-dimethyltetrahydropyr-2-on-derivate, verfahren zu ihrer herstellung und ihre verwendung zur synthese von pyretrinverbindungen.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee